+ Watch LCI
on My Watchlist
The Company develops, manufactures, markets and distributes generic versions of pharmaceutical products.
Pending lawsuit could impact company outlook.
Net sales have grown at a compounded annual growth rate of 24% since 2001. Small market cap giving it plenty of room to run. As health care costs continue to rise and the use of prescription medication continuing to increase more providers are looking for cheaper options in the generic drugs. This gives Lannett an opportunity to capitalize on this trend. They are also working on producing their own branded drug C-Topical. C-Topical is used for the introduction of local (topical) anesthesia for patients during ear, nose or throat surgery. It currently makes up 8% of net sales.
Taking advantage of short term price inflation on generics. I don't foresee this as sustainable, thus short term outperform...looking for a pop.
Affordable Care Act
cannot justify value at 23, see it at 9
charles schwab screener A+ Pharma Generic low PEG < 1
FDA approvals opened up after 483's were fixed.Backlog of approvals to comeCody labs starting to hit stride and provide profits.
Looks like morphine sulfate is the rage.
LCI seems to have plans for new products and marketing they look as if they will do well over the next few months holding their own while the market makes the necessasry corrections.
The stock has been on the rise as of late and is doing so on the back of solid financials. The company in the past five years has had a top out in the low twenties with similiar data to what it is displaying currently. 200% increase within the next 1-2 years.
Whoever said this stock is under valued needs to learn what value really is. LCI has a PE ratio over 100. The stock trades within 10% of its 52 week high. Returns on assets, equity, and capital is almost nothing. No dividend. Less than 2% profit margin is weak. This is not value. I want to see this stock drop down to $3 per share before I close this out.
Great business in a growth industry. Fundamentals look real solid.
New facilities, managment team refocused, many applications awaiting approval.
Seems underpriced given earnings projected by the lone analyst. Haven't had time to really dig into it though.
beaten, high value, lhigh growth, low price, rebounding
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions